Kyan Therapeutics, a biotech business, has secured $5 million in a pre-series A round that was oversubscribed and was headed by Altara Ventures.
Soon after reporting encouraging results from its clinical research on a guided therapy platform for patients with relapsed and refractory lymphoma, the Singapore-based company received the cash.
Through its technological platforms, Kyan seeks to find the most effective therapeutic combinations at various doses for anything from drug discovery to customized treatment.
“Singapore is the perfect place for us to set up our new global headquarters, given the access to strategic investors, leading clinical collaborators, and great talent,” Hugo Saavedra, Chairman and CEO of Kyan, said in a statement.
Gavin Teo, general partner at Altara Ventures, will join Kyan’s board of directors after the fundraising. The fundraising round also included participation from Seeds Capital and K3 Ventures.
